Lincoln Pharmaceuticals Ltd

- No specific mention of any current or planned fundraising through debt or equity in the transcript. - The company has substantial surplus cash and prefers to use it for inorganic growth or greenfield projects rather than paying dividends. - Promoters plan to gradually increase shareholding when additional funds are available, indicating internal funding prioritization. - No plans for share buybacks detailed. - Focus is on exploring inorganic growth opportunities, potentially funded through existing cash or future investments, but no explicit fundraising announced. - No direct references to upcoming debt issuances or equity offerings were made in the discussion.

- Lincoln Pharmaceuticals is exploring both organic and inorganic growth options. - They are considering setting up a new plant or acquiring through inorganic expansion to exceed current capacity. - Focus areas for inorganic expansion include tableting and injectable segments with required accreditations. - They are also investing in product registrations and regulatory approvals across markets like Canada, Latin America, Europe, with an annual budget of INR 5-7 crores for registrations, forming part of R&D and registration expenses. - The Cepha block (new factory in Mehsana) is operational, generating about INR 45 crores revenue this year, targeting INR 150 crores. - No explicit plans for diversification beyond the pharma segments mentioned, but exploring oncology and hormones. - Current cash holdings are being preserved for potential strategic inorganic investments or greenfield projects.

- Lincoln Pharmaceuticals targets INR1,000 crores revenue by FY 2028, possibly with a 5-6 months delay. - Current capacity utilization allows for a 15-20% increase in revenue without new plants. - New Cephalosporin block factory expected to generate around INR45 crores revenue this year, targeting INR150 crores eventually. - Growth avenues include organic expansion through new plants, inorganic expansion via acquisitions, and increased registrations. - Export markets (Africa, Latin America, Southeast Asia) and regulated markets (Canada, others) drive growth. - Domestic and export revenue mix targeted at approximately 60-40 to 65-35. - EBITDA margin expected between 15-18%, with possible upside. - Focus on branding and marketing to support volume and sales growth. - Ongoing product development aligned with existing manufacturing lines to optimize capacity.

- Lincoln Pharmaceuticals aims for a revenue growth rate between 15% to 18% for the next year, with potential to exceed 18%. - EBITDA margins are expected to remain around 15%, possibly expanding to 18%. - The company targets sustainable EBIT and profit growth through expansion in existing markets and inorganic growth opportunities. - EPS for 9 months FY '26 stands at INR 38.07, close to last year's full-year EPS of INR 41.11, indicating steady earnings progress. - The Cepha block factory is projected to contribute around INR 45 crores revenue by year-end, with growth expected in subsequent years. - Long-term revenue target is INR 1,000 crores by FY '28, with potential delays of 5-6 months but the goal remains firm. - The company prioritizes growing shareholder wealth and increasing profitability while maintaining financial prudence.

The transcript does not explicitly mention the current or expected order book or pending orders for Lincoln Pharmaceuticals Limited. However, from the information provided, we can infer the following: - The company is expecting revenues of around INR45 crores from the Cepha block (Mehsana factory) by the end of the current year. - Growth guidance targets a revenue milestone of INR1,000 crores by FY '28, with possible slight delays of up to 6 months. - Existing manufacturing capacity can potentially accommodate a 15% to 20% increase in revenues from the current base. - The company is exploring inorganic growth opportunities and new product registrations to achieve revenue targets. - No specific order book or pending order figures were disclosed in the call. Hence, current and expected order bookings remain unspecified publicly but indicate positive prospects based on capacity and product pipeline.